Reactivation of mTOR in acute kidney injury (AKI)
Inventors
Qiu, Andong • BEENKEN, Andrew • Barasch, Jonathan
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12691088-B2
Publication Date
2026-07-28
Expiration Date
Abstract
The subject method described herein relates to a method of treating, preventing, or reducing the incidence of Acute Kidney Injury (AKI) in a subject in need thereof by administering to the subject a pharmaceutically effective amount of one or more amino acids.
Core Innovation
The invention relates to infusion-based amino-acid therapy to treat, prevent, or reduce the incidence of acute kidney injury (AKI) in a subject in need thereof. The therapy administers a pharmaceutically effective amount of one or more amino acids selected from leucine, isoleucine, threonine, histidine, valine, arginine, glutamine, and aspartic acid, or combinations thereof, and the subject has disrupted mTOR signaling.
The invention further addresses diminished kidney function or renal failure when the diminished kidney function or renal failure is due to AKI and the subject has disrupted mTOR signaling. In the described framework, disrupted kidney endocytosis is associated with altered Sphingolipid Transporter 1 (Spns1) activity, and this association is linked to mTOR signaling.
The document connects the therapeutic use of amino acids to AKI indications that include ischemic AKI, rhabdomyolysis-induced AKI, and ischemia-reperfusion-induced AKI (iAKI). Reported therapeutic benefit is described in terms of decreased serum creatinine (sCr) and/or blood urea nitrogen (BUN) following amino-acid administration.
Claims Coverage
The patent contains two independent claims. Across these, the claim coverage centers on administering selected amino acids to subjects with disrupted mTOR signaling to treat, prevent, or reduce AKI-related outcomes.
Treating, preventing, or reducing AKI with amino acids under disrupted mTOR signaling
A method of treating, preventing, or reducing incidence of Acute Kidney Injury (AKI) in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of one or more amino acids, wherein the subject has disrupted mTOR signaling, and wherein the one or more amino acids is selected from leucine, isoleucine, threonine, histidine, valine, arginine, glutamine, aspartic acid, or a combination thereof.
Treating, preventing, or reducing diminished kidney function or renal failure due to AKI with amino acids under disrupted mTOR signaling
A method of treating, preventing, or reducing a diminished kidney function or a renal failure in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of one or more amino acids, wherein the diminished kidney function or renal failure of the subject is due to AKI and wherein the subject has disrupted mTOR signaling, and wherein the one or more amino acids is selected from leucine, isoleucine, threonine, histidine, valine, arginine, glutamine, aspartic acid, or a combination thereof.
Overall, the claim set requires a subject with disrupted mTOR signaling and administration of pharmaceutically effective amounts of amino acids selected from the specified leucine, isoleucine, threonine, histidine, valine, arginine, glutamine, and aspartic acid set, or combinations thereof, to achieve treatment, prevention, or reduction of AKI incidence or AKI-related diminished kidney function or renal failure.
Stated Advantages
Decreases serum creatinine (sCr) and/or blood urea nitrogen (BUN) after amino-acid administration.
Documented Applications
Treating, preventing, or reducing incidence of acute kidney injury (AKI), including ischemic AKI, rhabdomyolysis-induced AKI, and ischemia-reperfusion-induced AKI (iAKI).
Treating, preventing, or reducing diminished kidney function or renal failure when diminished kidney function or renal failure is due to AKI in a subject with disrupted mTOR signaling.
Interested in licensing this patent?